Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

Nature

Volumn 522, Issue 7555, 2015, Pages 216-220

  Najm, Fadi J ^a   Madhavan, Mayur ^a   Zaremba, Anita ^a   Shick, Elizabeth ^a   Karl, Robert T ^a   Factor, Daniel C ^a   Miller, Tyler E ^a,b   Nevin, Zachary S ^a   Kantor, Christopher ^a   Sargent, Alex ^a   Quick, Kevin L ^c   Schlatzer, Daniela M ^a   Tang, Hong ^d   Papoian, Ruben ^d   Brimacombe, Kyle R ^e   Shen, Min ^e   Boxer, Matthew B ^e   Jadhav, Ajit ^e   Robinson, Andrew P ^f   Podojil, Joseph R ^f   Miller, Stephen D ^f   Miller, Robert H ^a,g   Tesar, Paul J ^a   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c PERKINELMER INC   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; GLUCOCORTICOID RECEPTOR; MICONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; LYSOPHOSPHATIDYLCHOLINE;

BIOACTIVITY; DISEASE SEVERITY; DRUG; IMMUNE SYSTEM; NERVOUS SYSTEM; PROTEIN; RODENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SCREENING; ENZYME PHOSPHORYLATION; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; REMYELINIZATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; STEM CELL; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; ANIMAL; CEREBELLUM; CYTOLOGY; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GERM LAYER; MALE; METABOLISM; MYELIN SHEATH; PATHOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; REGENERATION; TISSUE CULTURE TECHNIQUE;

ANIMALS; CELL DIFFERENTIATION; CEREBELLUM; CLOBETASOL; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GERM LAYERS; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICONAZOLE; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; PHENOTYPE; PLURIPOTENT STEM CELLS; RECEPTORS, GLUCOCORTICOID; REGENERATION; TISSUE CULTURE TECHNIQUES;

EID: 84930349658     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14335     Document Type: Article

References (30)

1. Goldman, S. A., Nedergaard, M. & Windrem, M. S. Glial progenitor cell-based treatment and modeling of neurological disease. Science 338, 491-495 (2012).
2. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346, 165-173 (2002).
3. Najm, F. J. et al. Rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells. Nature Methods 8, 957-962 (2011).
4. Tesar, P. J. et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 448, 196-199 (2007).
5. Brons, I. G. et al. Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature 448, 191-195 (2007).
6. Mi, S. et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 65, 304-315 (2009).
7. Bai, L. et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nature Neurosci. 15, 862-870 (2012).
8. Deshmukh, V. A. et al. A regenerative approach to the treatment of multiple sclerosis. Nature 502, 327-332 (2013).
9. Mei, F. et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nature Med. 20, 954-960 (2014).
10. Fancy, S. P. et al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp. Neurol. 225, 18-23 (2010).
11. Franklin, R. J. & Ffrench-Constant, C. Remyelination in the CNS: from biology to therapy. Nature Rev. Neurosci. 9, 839-855 (2008).
12. Dubois-Dalcq, M., Ffrench-Constant, C. & Franklin, R. J. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 48, 9-12 (2005).
13. Barres, B. A., Lazar, M. A. & Raff, M. C. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 120, 1097-1108 (1994).
14. Woodruff, R. H. & Franklin, R. J. The expression of myelin basic protein exon 1 and exon 2 containing transcripts during myelination of the neonatal rat spinal cord-an in situ hybridization study. J. Neurocytol. 27, 683-693 (1998).
15. Woodruff, R. H. & Franklin, R. J. The expression of myelin protein mRNAs during remyelination oflysolecithin-induced demyelination. Neuropathol. Appl. Neurobiol. 25, 226-235 (1999).
16. Jeffery, N. D. & Blakemore, W. F. Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J. Neurocytol. 24, 775-781 (1995).
17. Kumar, S., Cole, R., Chiappelli, F. & de Vellis, J. Differential regulation of oligodendrocyte markers by glucocorticoids: post-transcriptional regulation of both proteolipid protein and myelin basic protein and transcriptional regulation of glycerol phosphate dehydrogenase. Proc. Natl Acad. Sci. USA 86, 6807-6811 (1989).
18. Morisaki, S. et al. Endogenous glucocorticoids improve myelination via Schwann cells after peripheral nerve injury: an in vivo study using a crush injury model. Glia 58, 954-963 (2010).
19. Ishii, A., Fyffe-Maricich, S. L., Furusho, M., Miller, R. H. & Bansal, R. ERK1/ERK2 MAPK signaling is required to increase myelin thickness independent of oligodendrocyte differentiation and initiation of myelination. J. Neurosci. 32, 8855-8864 (2012).
20. Fyffe-Maricich, S. L., Schott, A., Karl, M., Krasno, J. & Miller, R. H. Signaling through ERK1/2 controls myelin thickness during myelin repair in the adult central nervous system. J. Neurosci. 33, 18402-18408 (2013).
21. Hu, B. Y., Du, Z. W. & Zhang, S. C. Differentiation of human oligodendrocytes from pluripotent stem cells. Nature Protocols 4, 1614-1622 (2009).
22. Wang, S. et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12, 252-264 (2013).
23. Najm, F. J. et al. Isolation of epiblast stem cells from preimplantation mouse embryos. Cell Stem Cell 8, 318-325 (2011).
24. Najm, F. J. et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nature Biotechnol. 31, 426-433 (2013).
25. Wisniewski, J. R., Nagaraj, N., Zougman, A., Gnad, F. & Mann, M. Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J. Proteome Res. 9, 3280-3289 (2010).
26. Factor, D.C. et al. Epigenomic comparison reveals activationof"seed" enhancers during transition from naivetoprimed pluripotency. Cell Stem Cell 14, 854-863 (2014).
27. Cahoy, J. D. et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28, 264-278 (2008).
28. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
29. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnol. 28, 511-515 (2010).
30. Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature Biotechnol. 31, 46-53 (2013).